Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ambulatory Blood Pressure Monitoring Clear all
Completed Phase 3 Interventional Results available

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

NCT04467697
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
SOV2012-F1
Drug
Lead sponsor
Marius Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Mobile, Alabama • Aventura, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 1, 2026, 10:27 PM EDT
Completed No phase listed Observational

Ambulatory Blood Pressure Monitoring in Children

NCT01070342
View directory record Official record
Conditions
Blood Pressure
Interventions
Spacelabs 90217
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

NCT00034840
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan, valsartan
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

NCT00274599
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
19 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

NCT03868059
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
LPCN 1021
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

NCT00662896
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
57
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 1, 2026, 10:27 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Digital Home Blood Pressure Monitoring in Type B Aortic Dissection Patients

NCT04116684
View directory record Official record
Conditions
Aortic Dissection, Hypertension
Interventions
Withings Digital Blood Pressure Monitor
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

NCT02121041
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine, Chlorthalidone, Losartan
Drug
Lead sponsor
Anthony J Viera, MD, MPH
Other
Eligibility
30 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors

NCT02623036
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Equivalent dose enalapril, Equivalent dose lisinopril
Drug
Lead sponsor
Memorial Health University Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Virtual Reality as a Tool to Lower Blood Pressure and Anxiety in Clinic Settings

NCT06960057
View directory record Official record
Conditions
White Coat Hypertension, Hypertension, Blood Pressure, Anxiety, Virtual Reality Exposure Therapy, Ambulatory Blood Pressure Monitoring, Blood Pressure Disorders
Interventions
Virtual Reality Exposure
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 1, 2026, 10:27 PM EDT
Terminated Not applicable Interventional Results available

Management of Uncontrolled Hypertension (HTN)

NCT02922023
View directory record Official record
Conditions
Hypertension
Interventions
Ambulatory blood pressure monitor (ABPM), Chronotherapy
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Novel Approaches for Estimating Awake and Sleep Blood Pressure

NCT04307004
View directory record Official record
Conditions
Blood Pressure
Interventions
Unattended blood pressure measurement, Attended blood pressure measurement, Ambulatory blood pressure monitoring, Home blood pressure monitoring
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 87 Years
Enrollment
654 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

NCT00618956
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran hydrochloride, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Sep 1, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

NCT07240831
View directory record Official record
Conditions
Blood Pressure, Heart Disease, Hypertension (HTN), Blood Pressure Monitoring
Interventions
Model BB-613WP
Device
Lead sponsor
Biobeat Technologies Ltd.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants

NCT04320745
View directory record Official record
Conditions
Hypogonadism
Interventions
Androderm®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional

Vogelxo(R) ABPM Study in Hypogandal Men

NCT04558567
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Vogelxo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Anaheim, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

NCT05795153
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 1, 2026, 10:27 PM EDT
Not listed Phase 4 Interventional

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

NCT04976595
View directory record Official record
Conditions
Hypogonadism
Interventions
Natesto
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional

Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension

NCT00235001
View directory record Official record
Conditions
Hypertension
Interventions
trandolapril/verapamil
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

NCT00591266
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil and amlodipine, Amlodipine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

NCT00591253
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
60
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tempe, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 1, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury

NCT06841198
View directory record Official record
Conditions
Spinal Cord Injuries (SCI), Orthostatic Hypotension, Dysautonomic, Cardiovascular, Transcutaneous Spinal Stimulation
Interventions
spinal cord transcutaneous stimulation, Ice testing
Device · Procedure
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 1, 2026, 10:27 PM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Sep 1, 2026, 10:27 PM EDT